JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

Search

Omeros Corp

Gesloten

SectorGezondheidszorg

7.89 -4.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.75

Max

8.32

Belangrijke statistieken

By Trading Economics

Inkomsten

8M

-25M

Winstmarge

-8,121.359

Werknemers

202

EBITDA

9.3M

-26M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+59.27% upside

Dividenden

By Dow Jones

Volgende Winsten

12 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

284M

561M

Vorige openingsprijs

12.37

Vorige sluitingsprijs

7.89

Nieuwssentiment

By Acuity

31%

69%

76 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Omeros Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 okt 2025, 15:36 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 okt 2025, 13:27 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15 okt 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Peer Vergelijking

Prijswijziging

Omeros Corp Prognose

Koersdoel

By TipRanks

59.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.14 USD  59.27%

Hoogste 20 USD

Laagste 6.288 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Omeros Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technische score

By Trading Central

6.265 / 7.49Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

76 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat